Furafylline

Furafylline (CAS No.: 80288-49-9) is a synthetic methylxanthine derivative originally developed as a long-acting bronchodilator in the context of asthma research, distinguished by its extended duration of action relative to theophylline and subsequently recognized for its potent and highly selective inhibition of cytochrome P450 1A2 (CYP1A2). This compound functions as a mechanism-based inhibitor of CYP1A2, a key enzyme involved in the metabolic processing of xenobiotics and endogenous substrates, including the oxidation of caffeine, and exhibits strong inhibitory activity in the nanomolar range while demonstrating minimal effects on other major CYP isoforms such as CYP2D, CYP2C, CYP3A, and CYP1A1. Owing to this selectivity profile, furafylline is widely utilized in biochemical and pharmacological studies to investigate CYP1A2-mediated drug metabolism, enzyme kinetics, and drug–drug interaction mechanisms, as well as to delineate the contribution of this isoform in hepatic and extrahepatic systems. In vitro and in vivo experimental applications typically leverage its ability to selectively modulate CYP1A2 activity to probe metabolic pathways, validate target engagement, and support drug discovery efforts focused on metabolic stability and toxicity, with concentrations or dosing regimens adjusted according to specific experimental models and study objectives.